Literature DB >> 18691061

Airway fibrosis and angiogenesis due to eosinophil trafficking in chronic asthma.

Seema S Aceves1, David H Broide.   

Abstract

Asthma is characterized by the presence of increased numbers of inflammatory cells in the airway in particular eosinophils and Th2 lymphocytes. In addition to the presence of inflammatory cells, the airways of patients with asthma exhibit varying levels of structural changes termed airway remodeling. These structural changes include subepithelial fibrosis, smooth muscle hypertrophy/hyperplasia, epithelial cell mucus metaplasia, and increased angiogenesis. This review focuses on the potential role of the eosinophil in promoting features of airway remodeling including fibrosis and neovascularization in chronic asthma. Eosinophils may potentially contribute to airway remodeling through release of eosinophil derived mediators such as TGFbeta which act directly upon target fibroblasts to promote fibrosis. In addition to the potential importance of the eosinophil to remodeling in asthma, eosinophilic esophagitis (EE) is another eosinophil associated disease that is associated with increased levels of esophageal eosinophils, increased levels of TGFbeta expression, and increased levels of fibrosis, suggesting that a similar mechanism of remodeling may contribute to both of these eosinophil associated diseases. However, remodeling in both asthma and EE is likely complex involving both eosinophil dependent and eosinophil independent pathways. Further studies in both humans and animal models will help to increase our knowledge of the contribution of the eosinophil to remodeling in asthma as well as EE.

Entities:  

Mesh:

Year:  2008        PMID: 18691061     DOI: 10.2174/156652408785161023

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  32 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 2.  Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.

Authors:  Seema S Aceves; Steven J Ackerman
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

Review 3.  Eosinophils and disease pathogenesis.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

Review 4.  What targeting eosinophils has taught us about their role in diseases.

Authors:  Bruce S Bochner; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

5.  Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo.

Authors:  Ting Wen; John A Besse; Melissa K Mingler; Patricia C Fulkerson; Marc E Rothenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

6.  A halotyrosine antibody that detects increased protein modifications in asthma patients.

Authors:  Hongjun Jin; Teal S Hallstrand; Don S Daly; Melissa M Matzke; Parameswaran Nair; Diana J Bigelow; Joel G Pounds; Richard C Zangar
Journal:  J Immunol Methods       Date:  2013-12-02       Impact factor: 2.303

Review 7.  Type 2 immunity in tissue repair and fibrosis.

Authors:  Richard L Gieseck; Mark S Wilson; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

8.  From genetics to treatment of eosinophilic esophagitis.

Authors:  Antonella Cianferoni; Jonathan M Spergel
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-10

Review 9.  Eosinophil-derived cytokines in health and disease: unraveling novel mechanisms of selective secretion.

Authors:  R C N Melo; L Liu; J J Xenakis; L A Spencer
Journal:  Allergy       Date:  2013-01-25       Impact factor: 13.146

Review 10.  Group 2 innate lymphoid cells in lung inflammation.

Authors:  Bobby W S Li; Rudi W Hendriks
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.